Connect with us

Biotechnology

G1 Therapeutics to Provide Second Quarter 2020 Corporate and Financial Update on August 5, 2020

Avatar

Published

on

RESEARCH TRIANGLE PARK, N.C., July 29, 2020 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2020 on Wednesday, August 5, 2020 at 5:00 p.m. ET.

The live call may be accessed by dialing 866-763-6020 (domestic) or 210-874-7713 (international) and entering the conference code: 4648036. The live and archived webcast will be available on the Events & Presentations page of the G1 website.

About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib is a first-in-class FDA-designated Breakthrough Therapy designed to improve outcomes for patients being treated with chemotherapy. Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. Lerociclib is a differentiated oral CDK4/6 inhibitor designed to enable more effective combination treatment strategies.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:
Jeff Macdonald
Senior Director, Investor Relations & Corporate Communications
919-907-1944
jmacdonald@g1therapeutics.com

Primary Logo

Source: https://www.biospace.com/article/releases/g1-therapeutics-to-provide-second-quarter-2020-corporate-and-financial-update-on-august-5-2020/?s=75

Biotechnology

Perceptive debuts LianBio with cancer and heart disease programs from BridgeBio, MyoKardia

Avatar

Published

on

After working in stealth since October, Perceptive Advisors is unveiling its latest biotech: LianBio, which serves the dual mission of bringing much-needed new drugs to China and helping U.S. biotech companies expand their operations into Asia.

LianBio launches with a trio of assets licensed from MyoKardia and BridgeBio Pharma companies Navire Pharma and QED Therapeutics. LianBio is handing over more than $60 million upfront in exchange for development and commercialization rights to the programs in China and “selected Asian markets.” BridgeBio and MyoKardia will pick up equity in the LianBio, too.

And that’s not all—LianBio has a “strategic relationship” with BridgeBio that gives it first dibs on the 20 programs already in the latter’s pipeline, as well as any assets it may bring under its umbrella in the next four years, said Konstantin Poukalov, a managing director at Perceptive Advisors and executive chairman of LianBio. The company will be on the hook for up to $505 million in milestone payments to BridgeBio and $147.5 million to MyoKardia.

Sponsored by Biotech Primer

September 2-3, 2020 Live, Online Course: Biopharma Revenue Forecasting that Drives Decision Making and Investments

Become fluent in the core elements of revenue forecasting including epidemiology, competitive assessments, market share assignment and pricing. Let Biotech Primer’s dynamic industry experts teach you how to assess the value of new therapies.

LianBio’s pipeline includes mavacamten—a treatment for hypertrophic cardiomyopathy (HCM), an inherited disorder that causes the muscle walls of the heart to thicken, potentially to the point where they can obscure blood flow. MyoKardia plans to submit the drug for FDA approval for obstructive HCM in early 2021 and continue to develop it for patients with the non-obstructive form of HCM and those with a specific kind of heart failure, in which the left ventricle can’t properly fill with blood and pumps less blood to the body than normal.

RELATED: GlaxoSmithKline veteran Zhi Hong launches Brii Biosciences with $260M

LianBio has also licensed infigratinib, QED Therapeutics’ EGFR inhibitor that’s in a phase 3 study for bile duct cancer, and a SHP2 inhibitor that Navire Pharma is developing for drug-resistant tumors and other hard-to-treat cancers. LianBio hands over $26.5 million upfront

The company views these as more than just licensing deals, Debra Yu, LianBio’s chief business officer said. It plans to pitch in and run clinical trials in China and other parts of Asia where appropriate.

“It isn’t just like we get mavacamten and we go wherever we want with it and pay them the royalties,” Yu said.

“In the case of mavacamten, MyoKardia already got it all the way through for the obstructive HCM indication and we’ll take it into China,” she added. “But for the other indications, in nonobstructive HCM and (heart failure with preserved ejection fraction), we will work side by side with them.”

As for infigratinib, that could mean testing the drug in cancers that QED is not yet looking at, but that are prevalent in China, such as gastric cancer, she added.

It’s part of Perceptive and LianBio’s bid to bring cutting-edge medicines to China and address what CEO Bing Li calls the gap between global innovation and the China market.

“China has predominantly been a generics market for most of its time,” Yu said. “Even today, there is still a very limited number of innovative drugs and certainly not those we would call ‘paradigm-shifting.”

As it advances its pipeline, LianBio aims to double its team by the end of the year. It will be on the hunt for more assets that it might want to pursue in China, both through its deal with BridgeBio and other potential partners.

When asked if LianBio would ever dive into in-house discovery and development, Poukalov said “nothing is ever off the table,” but that the core focus of the company’s model is “high-quality assets that are highly significantly derisked.”

“But once our therapeutic areas of focus are established, we are certainly willing to move to earlier stages of development,” Poukalov added. That could include putting together novel cancer-fighting combinations based on Navire’s SHP2 inhibitor.

“In the near-term, I don’t think we are going to be doing true benchwork—there are plenty of people who are good at doing that—but we will be utilizing what we know and the access we have to be creative and do early-stage development work,” he said.

Editor’s note: This story has been updated to remove the dollar amount of LianBio’s funding as it was incorrect.

Source: https://www.fiercebiotech.com/biotech/perceptive-debuts-lianbio-cancer-and-heart-disease-programs-from-bridgebio-myokardia

Continue Reading

Biotechnology

SMART research enhances dengue vaccination in mice

Avatar

Published

on

Researchers from the Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, have found a practical way to induce a strong and broad immunity to the dengue virus based on proof-of-concept studies in mice. Dengue is a mosquito-borne viral disease with an estimated 100 million symptomatic infections every year. It is endemic in over 100 countries in the world, from the United States to Africa and wide swathes of Asia. In Singapore, over 1,700 dengue new cases were reported recently. 

The study is reported in a paper titled “Sequential immunization induces strong and broad immunity against all four dengue virus serotypes,” published in NPJ Vaccines. It is jointly published by SMART researchers Jue Hou, Shubham Shrivastava, Hooi Linn Loo, Lan Hiong Wong, Eng Eong Ooi, and Jianzhu Chen from SMART’s Infectious Diseases and Antimicrobial Resistance (AMR) interdisciplinary research groups (IRGs). 

The dengue virus (DENV) consists of four antigenically distinct serotypes and there is no lasting immunity following infection with any of the DENV serotypes, meaning someone can be infected again by any of the remaining three variants of DENVs.

Today, Dengvaxia is the only vaccine available to combat dengue. It consists of four variant dengue antigens, one for each of the four serotypes of dengue, expressed from attenuated yellow-fever virus. The current three doses of immunization with the tetravalent vaccine induce only suboptimal protection against DENV1 and DENV2. Furthermore, in people who have not been infected by dengue, the vaccine induces a more severe dengue infection in the future. Therefore, in most of the world, the vaccination is only given to those who have been previously infected. 

To help overcome these issues, SMART researchers tested on mice whether sequential immunization (or one serotype per dose) induces stronger and broader immunity against four DENV serotypes than tetravalent-formulated immunization — and found that sequential immunization induced significantly higher levels of virus-specific T cell responses than tetravalent immunization. Moreover, sequential immunization induced higher levels of neutralizing antibodies to all four DENV serotypes than tetravalent vaccination.

“The principle of sequential immunization generally aligns with the reality for individuals living in dengue-endemic areas, whose immune responses may become protective after multiple heterotypic exposures,” says Professor Eng Eong Ooi, SMART AMR principal investigator and senior author of the study. “We were able to find a similar effect based on the use of sequential immunization, which will pave the way for a safe and effective use of the vaccine and to combat the virus.”

Upon these promising results, the investigators will aim to test the sequential immunization in humans in the near future.

The work was supported by the National Research Foundation (NRF) Singapore through the SMART Infectious Disease Research Program and AMR IRG. SMART was established by MIT in partnership with the NRF Singapore in 2007. SMART is the first entity in the Campus for Research Excellence and Technological Enterprise (CREATE) developed by NRF.  SMART serves as an intellectual and innovation hub for research interactions between MIT and Singapore, performing cutting-edge research of interest to both Singapore and MIT. SMART currently comprises an Innovation Centre and five IRGs: AMR, Critical Analytics for Manufacturing Personalized-Medicine, Disruptive and Sustainable Technologies for Agricultural Precision, Future Urban Mobility, and Low Energy Electronic Systems. SMART research is funded by the NRF Singapore under the CREATE program.  

The AMR IRG is a translational research and entrepreneurship program that tackles the growing threat of antimicrobial resistance. By leveraging talent and convergent technologies across Singapore and MIT, they aim to tackle AMR head-on by developing multiple innovative and disruptive approaches to identify, respond to, and treat drug-resistant microbial infections. Through strong scientific and clinical collaborations, they provide transformative, holistic solutions for Singapore and the world.


Source: http://news.mit.edu/2020/smart-researchers-enhance-dengue-vaccination-mice-0811

Continue Reading

Biotechnology

Medtronic snaps up smart insulin pen maker Companion Medical in a ‘bold move’

Avatar

Published

on

Medtronic is buying up leading smart insulin pen and phone app maker Companion Medical as it looks to shore up its growing weakness in the pump market.

The med tech major gets access to Companion’s InPen, a so-called smart insulin pen that not only delivers insulin, but also tracks insulin on board, provides an meal bolus calculator and shares information with connected systems.

The InPen last for around a year and works with short-acting insulins, although work is being done on long-acting insulins. The company made around $11 million in 2019 sales and was looking to triple that this year, after launching in late 2017, though its market penetration is pretty low.

Sponsored by Biotech Primer

September 2-3, 2020 Live, Online Course: Biopharma Revenue Forecasting that Drives Decision Making and Investments

Become fluent in the core elements of revenue forecasting including epidemiology, competitive assessments, market share assignment and pricing. Let Biotech Primer’s dynamic industry experts teach you how to assess the value of new therapies.

“This acquisition is an ideal strategic fit for Medtronic as we further simplify diabetes management and improve outcomes by optimizing dosing decisions for the large number of people using multiple daily injection (MDI),” said Sean Salmon, EVP and president of the Diabetes Group at Medtronic.

“We look forward to building upon the success of the InPen by combining it with our intelligent algorithms to deliver proactive dosing advice personalized to each individual. This smart CGM system can help people think less about diabetes and be able to live life with more freedom, on their own terms.

”Our goal is to become a trusted partner that offers consistent support whether an individual wants to stay on MDI, transition to automated insulin delivery or take a break from their pump.”

Analysts at Jefferies said the buyout was a “bold move” and a “source of growth” for Medtronic, and could add $200 million in incremental revenue.  

It points out that Medtronic has “been floundering in diabetes,” losing around a point of share a month in the pump market. The Companion deal will help offset this, and allows Medtronic to serve not only the current and future pump market, but also those that chose to stay on pens, Jefferies said in a note the clients.

The plan now is to combine its diabetes tools (from its Nutriono and Klue buyouts) with InPen and integrate its own continuous glucose monitoring (CGM) system.

Jefferies notes however that the future of insulin delivery “remains a debate.” They firm muses whether smart pens “provide enough of a clinical leap for patients such that pumps prove too much of a relative burden for their benefits.”

Financial details of the deal were not made public. Medtronic’s shares were up nearly 2% Tuesday.

Source: https://www.fiercebiotech.com/medtech/medtronic-snaps-up-smart-insulin-pen-maker-companion-medical-a-bold-move

Continue Reading
Nano Technology5 hours ago

SEMI Partners with GLOBALFOUNDRIES to Offer Apprenticeship Program Aimed at Building the Electronics Talent Pipeline

Fisher Yu, University of Arkansas CREDIT University of Arkansas
Nano Technology5 hours ago

Materials science researchers develop first electrically injected laser: The diode laser uses semiconducting material germanium tin and could improve micro-processing speed and efficiency at much lower costs

Nano Technology5 hours ago

Advance in programmable synthetic materials: Reading sequence of metal atoms in MOFs allows encoding of multiple chemical functions

Blockchain5 hours ago

Invest 3% in Bitcoin to Avoid COVID-19 Lockdown Devaluation — BitGo CEO

Blockchain5 hours ago

Cointelegraph Launches Newsletter for Professional Investors

Blockchain6 hours ago

Bitcoin Cash short-term Price Analysis: 12 August

Blockchain6 hours ago

Token Launches From Ethereum to Telegram: Where Do We Go From Here?

AR/VR6 hours ago

Enterprise VR Hardware Specialist Varjo Raises $54 Million in Latest Funding Round

Blockchain7 hours ago

Grayscale Bitcoin Trust Saw Surge in Investor Interest After March

Blockchain7 hours ago

VeChain & Oxford Announce New Framework to Assess Consensus Protocols

Blockchain7 hours ago

Championing Blockchain Education in Africa: Women Leading the Bitcoin Cause

Gaming7 hours ago

Evening Reading – August 11, 2020

Blockchain7 hours ago

Chainlink: Traders under zero loss, but why?

Blockchain8 hours ago

The Babylon Project: A Blockchain Focused Hackathon with a Commitment to Diversity & Inclusion

AR/VR8 hours ago

Varjo Raises $54M Financing to Support Its Retina-Quality VR/AR Headsets for Enterprise

Blockchain8 hours ago

Ethereum, Zcash, Dogecoin Price Analysis: 12 August

Blockchain9 hours ago

Peer-to-Peer Exchange CryptoLocally Now Offers Instant Credit Card Payment

Blockchain9 hours ago

Cardano (ADA) Holds On to Crucial Support By a Thread

Blockchain10 hours ago

Bitcoin Creates Double-Top After Failing Close Above $12,000

Blockchain11 hours ago

DeFi Farmers Rush to Yam and Serum for Explosive Yields

Energy12 hours ago

Copper Foil Market Size Worth $10.3 Billion By 2027 | CAGR: 9.7%: Grand View Research, Inc.

Energy12 hours ago

Corundum Market Size Worth $3.5 Billion By 2027 | CAGR: 4.0%: Grand View Research, Inc.

AR/VR12 hours ago

Mozilla is Shuttering its XR Team Amidst Major Layoff, But ‘Hubs’ Will Continue

Energy13 hours ago

New Energy Challenger, Rebel Energy, Places Blue Prism Digital Workers at the Heart of its Launch Plans

Science13 hours ago

Teknosa grows by 580 percent in e-commerce and pulls its operating profit into positive territory in Q2, despite the pandemic

Science13 hours ago

Novo Ventures Portfolio Company F2G Closes US$60.8 Million Financing

Science13 hours ago

F2G Closes US$60.8 Million Financing to fund late stage development of novel mechanism antifungal agent

Blockchain13 hours ago

LocalCryptos Integrates Inbuilt Crypto-To-Crypto Exchanges, Powered by ChangeNOW

Publications13 hours ago

Putin’s plan for Russia’s coronavirus vaccine is at ‘high risk of backfiring,’ expert says

Publications14 hours ago

UK enters recession after GDP plunged by a record 20.4% in the second quarter

Gaming14 hours ago

Another Steam Game Festival Is Coming In October

Science14 hours ago

Top 25 Nationally Ranked Carr, Riggs & Ingram (CRI) Welcomes Cookeville-Based Firm, Duncan, Wheeler & Wilkerson, P.C.

Science14 hours ago

Avast plc Half Year Results For The Six-Months Ended 30 June 2020

Cyber Security14 hours ago

Russian hackers steal Prince Harry and Meghan Markle photos via Cyber Attack

Gaming14 hours ago

Oddworld: New ‘N Tasty Coming To Switch In October

Gaming14 hours ago

Linkin Park’s Mike Shinoda Is Writing A Song For Gamescom 2020

Cyber Security14 hours ago

Texas School District experiences DDoS Cyber Attack

Gaming14 hours ago

‘EVE: Echoes’ from CCP Games and Netease Is Now Available Early on the App Store, Servers Go Live Tomorrow

Gaming14 hours ago

Hans Zimmer Created An Extended Netflix “Ta Dum” Sound For Theatres

Cannabis14 hours ago

Everything you need to know about the Exxus Snap VV

Trending